Copeptin: Disease Severity Indicator

Status Completed

Clinical Trial Summary

Copeptin serves as a biomarker emanating from the pituitary gland, functioning as the precursor to arginine vasopressin (AVP). Its role in the regulation of endothelial dysfunction, inflammation, and water-electrolyte balance has been established. The measurement of AVP levels poses challenges due to its brief half-life and the intricate nature of its detection method. In contrast, copeptin provides an indirect means of gauging circulating AVP levels, as it can be conveniently assessed through a sandwich immunoassay. As a neuroendocrine stress hormone, copeptin emerges as a prognostic indicator, reflective of an individual's stress burden. Moreover, its applicability extends to various acute conditions such as ischemic stroke or myocardial infarction. Notably, copeptin proves to be a dependable tool in the differential diagnosis of diverse ailments characterized by polyuria and polydipsia. Lower respiratory tract infection (LRTI) stands as the predominant cause of morbidity and mortality among children and adolescents globally. Notably, copeptin has demonstrated utility in forecasting the severity and complications associated with severe pneumonia in adults. While early investigations into copeptin's role in pediatric LRTI suggest its potential for diagnosing pneumonia and predicting complications, the outcomes of these studies present conflicting results. Although there has been a notable increase in studies on copeptin in pediatric patients over the past decade, research specifically exploring its correlation with pneumonia remains scarce. This prospective case-control study is designed to investigate the potential association between copeptin levels and the severity of illness in pediatric patients with pneumonia. The study aims to determine whether copeptin levels can serve as a reliable predictor of disease severity in pneumonia, offering valuable insights for clinical application. The outcomes of this research may contribute significantly to our comprehension of copeptin's role in disease prognosis and management, thereby facilitating the development of more efficacious diagnostic and therapeutic approaches. Additionally, the study seeks to identify the factors influencing copeptin levels and establish a cut-off value for copeptin in pediatric patients diagnosed with pneumonia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Bronchopneumonia
Lobar Pneumonia
Lower Respiratory Tract and Lung Infections
Pneumonia
Ventilator Lung

Clinical Trial Details

NCT number	NCT06211985
Study type	Interventional
Source	Haseki Training and Research Hospital
Contact
Status	Completed
Phase	N/A
Start date	April 12, 2023
Completion date	November 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03909854` - Pragmatic Investigation of Volume Targeted Ventilation-1	N/A
Completed	`NCT05690867` - Pressure Controlled Ventilation Versus Volume Controlled Ventilation in Upper Abdominal Surgery	N/A
Enrolling by invitation	`NCT06151886` - Life-dependent Home Mechanical Ventilation
Not yet recruiting	`NCT04229810` - Individualized Perioperative Open Lung Ventilatory Approach in Emergency Abdominal Laparotomy. A Prospective Multicenter Randomized Controlled Trial.	N/A
Recruiting	`NCT06051188` - FCV vs PCV in Moderate to Severe ARDS	N/A
Completed	`NCT04497090` - Adaptive Non-invasive Ventilation to Abolish Tidal Flow Limitation	N/A
Recruiting	`NCT06142474` - SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning	Phase 3
Completed	`NCT04581642` - Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report
Recruiting	`NCT05134467` - Assessment of Process and Outcome of Protocol-based Weaning From Mechanical Ventilation in the Medical Patients
Recruiting	`NCT05812365` - Best End-Expiratory and Driving-pressure for Individualized Flow Controlled Ventilation in Patients With COPD
Recruiting	`NCT04376307` - Minimal Flow Application in One Lung Ventilation	N/A
Recruiting	`NCT04484727` - "Lung Barometric Measurements in Normal And in Respiratory Distressed Lungs"
Completed	`NCT03411239` - Airway Pressure Changes Using Esophageal Balloon Catheter (OBC) in Laparoscopic Surgery	N/A
Recruiting	`NCT05116839` - Pressure Support Ventilation Versus Continuous Positive Air Way Pressure (CPAP) Using I Gelin Adult Patients,	N/A
Recruiting	`NCT03420417` - Respiratory Mechanics in Intensive Care Patients	N/A
Completed	`NCT04258202` - Ventilator-driven Alveolar Recruitment Maneuver	N/A
Recruiting	`NCT04307459` - Acute Respiratory Failure and COVID-19 in Real Life
Not yet recruiting	`NCT05726578` - Integrated Echocardiography and Chest Ultrasound Assessment of Lung Recruitment in Preterm Infants	N/A
Completed	`NCT03558620` - Effect of an Endoscopic Bite Block on Mask Ventilation	N/A
Completed	`NCT03226925` - Mechanically-assisted Ventilation in the Treatment of Moving Tumours With Photon and Proton Therapies	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.